John Dimar II, MD, and Steven Glassman, MD, spine surgeons with Norton Healthcare in Louisville, Ky., have been cited by The Spine Journal as two of the surgeons who co-authored studies that under-reported complications associated with Medtronic's Infuse, according to a Courier-Journal report.
Drs. Dimar and Glassman co-authored three of the 13 papers based on studies sponsored by Medtronic. An article in The Spine Journal authored by Eugene Carragee, MD, recently concluded that the risk of adverse events was 10-50 times higher than was reported in the original papers.
Dr. Glassman subsequently wrote an article for The Spine Journal showing the adverse events associated with Infuse. He was among the Norton physicians who reported that high doses of the bone morphogenic protein resulted in significant complications when used for anterior cervical fusions, which is off-label use.
According to the report, Medtronic disclosures indicate that both surgeons received $2.4 million from the company from Jan. 2010-March 2011, but the compensation was mostly due to royalties for a spinal implant system they previously helped develop.
Read the report on Infuse.
Related Articles on Infuse:
To Infuse or Not to Infuse: The Feud Between Spine Surgeons Continues
Infuse Lawsuits Begin: Negative coverage Could Cost Medtronic Millions
Senate Investigates Medtronic's Influence Over Surgeons Studying Infuse
Dr. Glassman subsequently wrote an article for The Spine Journal showing the adverse events associated with Infuse. He was among the Norton physicians who reported that high doses of the bone morphogenic protein resulted in significant complications when used for anterior cervical fusions, which is off-label use.
According to the report, Medtronic disclosures indicate that both surgeons received $2.4 million from the company from Jan. 2010-March 2011, but the compensation was mostly due to royalties for a spinal implant system they previously helped develop.
Read the report on Infuse.
Related Articles on Infuse:
To Infuse or Not to Infuse: The Feud Between Spine Surgeons Continues
Infuse Lawsuits Begin: Negative coverage Could Cost Medtronic Millions
Senate Investigates Medtronic's Influence Over Surgeons Studying Infuse